- $525.08m
- $228.05m
- $0.04m
Altimmune falls as CEO Vipin Garg to step down
Brief: Altimmune Announces CEO Transition, Succession Plan
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Altimmune Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing
Brief: Altimmune Files For Offering Of Common Stock Of Up To $200 Million - Filing
Brief: Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing
Altimmune Q3 revenue beats expectations
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences
Obesity drugmakers slip after Trump vows to lower weight-loss drug prices
U.S. STOCKS ON THE MOVE- Oklo, Boston Scientific, Agios
Obesity drugmakers slip after Trump vows to lower weight-loss drug prices
Brief: Altimmune Appoints Linda M. Richardson As Chief Commercial Officer
Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary
Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview
Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, AbbVie, McDonald's